57052-72-9

Usage

Uses

Used in Pharmaceutical Research:
3,4-dihydro-2H-chromen-7-ol is utilized as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential biological activities. Its presence in organic synthesis facilitates the development of new drugs with diverse therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3,4-dihydro-2H-chromen-7-ol serves as a valuable tool for understanding the structure-activity relationships of chromene compounds. Its study aids in the design and optimization of novel therapeutic agents with improved efficacy and selectivity.
Used in Drug Development:
3,4-dihydro-2H-chromen-7-ol is employed as a precursor in the development of new drugs, particularly those targeting oxidative stress and cancer. Its antioxidant and antitumor properties make it a promising candidate for the creation of innovative pharmaceuticals with potential therapeutic benefits.
Used in Antioxidant Applications:
3,4-dihydro-2H-chromen-7-ol is used as an antioxidant agent for its ability to neutralize free radicals and protect cells from oxidative damage. This application is crucial in the prevention and treatment of various diseases associated with oxidative stress.
Used in Antitumor Applications:
In the context of antitumor applications, 3,4-dihydro-2H-chromen-7-ol is used to target and inhibit the growth of cancer cells. Its potential to interfere with tumor progression makes it a valuable component in the development of anticancer drugs.
Used in Organic Synthesis Industry:
3,4-dihydro-2H-chromen-7-ol is used as a building block in the organic synthesis industry for the creation of complex organic molecules. Its versatility and reactivity contribute to the synthesis of a wide range of chemical products, including pharmaceuticals, agrochemicals, and specialty chemicals.

Upstream product

• 76240-27-2 7-hydroxy-2,3-dihydro-4H-chromen-4-one 
• 5751-52-0 7-methoxy-4H-chromen-4-one 
• 853760-23-3 7-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}-2,3-dihydro-4H-chromen-4-one 
• 30113-83-8 7-hydroxy-4-oxo-4H-chromene-2-carboxylic acid 
• 860189-36-2 4-(4-benzyloxy-2-hydroxy-phenyl)-2,4-dioxo-butyric acid ethyl ester 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 93-35-6 7-hydroxy-2H-chromen-2-one 
• 6345-73-9 7-benzyloxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester 
• 59887-89-7 7-hydroxy-4H-chromen-4-one 
• 18385-89-2 3-chromene 
• 108-46-3 recorcinol 
• 151884-07-0 2',4'-dihydroxy-3-chloropropiophenone 
• 3875-77-2 7-methoxychroman 

Downstream Products

• 1253524-14-9 7-benzoyloxychroman 
• 1243202-68-7 7-(4-methoxybenzoyloxy)chroman 
• 1243202-69-8 7-hydroxy-6-(4-methoxybenzoyl)chroman 
• 1243202-04-1 2-benzoyl-3-(4-methoxyphenyl)-6,7-dihydrogen-5H-furo[3,2-g]chromene 
• 1222555-16-9 1-(diphenylmethyl)-3-hydroxy-3-(7-hydroxy-3,4-dihydro-2H-chromen-6-yl)-1,3-dihydro-2H-indol-2-one 
• 102026-86-8 1-(7-hydroxy-chroman-6-yl)-ethanone-(2,4-dinitro-phenylhydrazone) 

Relevant academic research and scientific papers

FURO[3,2-G]CHROMENE COMPOUNDS AND USES THEREOF

Disclosed are furo[3,2-g]chromene derivatives represented by formula (I), stereoisomers, pharmaceutically acceptable salts, and pharmaceutical compositions thereof, as well as uses thereof as estrogen receptor modulators.

SPIROCYCLIC COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS

The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions modulated by VGSCs. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions by modulators of VGSC of Formula (I).

Synthesis, characterization, crystal structure and cytotoxicities of 2-aroyl-3-aryl-5H-furo[3,2-g]chromene derivatives

Five 2-aroyl-3-aryl-5H-furo[3,2-g]chromene derivatives have been synthesized, and their structures were characterized by IR, NMR, ESI-MS and elemental analysis. The crystal structure for 2-benzoyl-3-(4-methoxyphenyl)-6,7- dihydro-5H-furo[3,2-g]chromene has been determined by single-crystal X-ray diffraction. X-ray analysis reveals that the pyran ring adopts a half-chair conformation, while the fused furo[3,2-g]chromene ring is approximately coplanar with a slight distortion. The preliminary pharmacological test showed all target compounds exhibit cytotoxicities against the U2OS-EGFP-4F12G cell line. ARKAT USA, Inc.

HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy} phenyl)propanoic acid: A brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2)

We have identified and synthesized a brain penetrant propanoic acid as an allosteric potentiator of the metabotropic glutamate receptor 2. Structure-activity relationship studies directed toward improving the potency, level of potentiation and brain penetration led to the discovery of 8 (EC 50 = 1200 nM, 77% potentiation, 119% brain/plasma in rat, 20 mpk ip, brain level of 5700 nM).

Aromatic urea derivatives and their use as herbicide

This invention relates to novel compounds of formula [I], a process for their production, and their use as a herbicide. STR1 wherein A represents the bond STR2 in which X is a hydrogen atom, a chlorine atom, a nitro group or a trifluoromethyl group; B represents a hydrogen atom, a methyl group or a methoxy group; and Ar represents one member selected from the group consisting of STR3 in which R1 to R38, are as defined hereinafter.